Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study
Anish Thomas(National Cancer Institute), Stephen M. Hewitt(National Institutes of Health), Nitin Roper(Center for Cancer Research), Javed Khan(Kent State University), Éva Szabó(National Cancer Institute), Mark Raffeld(National Cancer Institute), Liqiang Xi(Center for Cancer Research), Jane B. Trepel(National Institutes of Health), Yves Pommier(National Cancer Institute), Seth M. Steinberg(National Institutes of Health), Samantha Nichols(National Cancer Institute), Venkatesh Krishnasamy(National Institutes of Health), Yuanbin Chen(Peking University Shenzhen Hospital), Andy Mammen(National Institute of Arthritis and Musculoskeletal and Skin Diseases), Rebecca Erwin-Cohen(National Cancer Institute), Christopher Trindade(Center for Cancer Research), Howard A. Young(National Cancer Institute), Fang Yin(Western Maryland Health System), Vamsidhar Velcheti(New York University), Rasa Vilimas(National Cancer Institute), Elliot Levy(National Institutes of Health)
Cited by 183
Related Papers
Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks
|Nature Medicine|2001|2.7k
Targeting the dynamic HSP90 complex in cancer
|Nature reviews. Cancer|2010|1.5k
Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses
|Cancer Research|2012|941
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817